Wednesday, October 21, 2026

°

GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure

Posted Wednesday, October 21, 2026 2:38 pm

Frank Vinluan (via MedCity News)

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure appeared first on MedCity News.

Continue reading at MedCity News »

Keywords

BioPharma, Legal, Pharma, antisense oligonucleotide, antiviral, Clinical Trials, FDA, GSK, hepatitis B, infectious disease, Ionis Pharmaceuticals

Top stories

Why Women Should Find Out Their Breast Cancer Risk Earlier than You Think

(NewsUSA) - For many people, breast cancer screening becomes a priority around age 40. However, according to recommendations from the American College of Radiology® (ACR®), one of the most …

Ask About Clinical Trials on Day One

(Mitch Jelniker) - For people diagnosed with small cell lung cancer, the clinical trial conversation belongs in the very first appointment.A diagnosis of SCLC can trigger a whirlwind of appointments, …

From Uncertainty to Reassurance: How a Small Heart Monitor and Ablation Procedure Helped One Father Conquer the Unknowns of Atrial Fibrillation

(NewsUSA) - In 2018, then-52-year-old Todd Repass Jr. stood up after a meal and immediately knew something was wrong. It was terrifying. He felt weak, short of breath, and, at times, dizzy. The …

Youth Tobacco Use Is at Historic Lows. Adult Smokers Still Need Better Choices.

(Dr. Matthew Holman) - There is a piece of good public health news that deserves more attention: youth tobacco use in the United States has fallen to historically low levels. That progress did not …

America’s New Drug Dealers Have Moved from Street Corners to the Internet – and the FDA is Letting Them

(Peter Pitts, President and Co-founder of the Center for Medicine in the Public Interest ) - Consumers purchasing retatrutide online may think they are buying a safe, clinically tested weight-loss …

From the web

AINewsBreaks – AZIO AI Holdings Inc. (NASDAQ: AZIO) Launches Atlas One to Address Growing AI Power Demand

AZIO AI Holdings (NASDAQ: AZIO) has unveiled Atlas One, a South Texas data center campus designed to address growing AI computing demand by developing dedicated, on-site power infrastructure. …

AINewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Expands Overwatch Strategy Across Drone Manufacturers, Government Markets

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) is developing a network-based approach to GPS-denied …

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Aims for Greater Precision in Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues. At the center of its strategy …

GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from …

AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovation

As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a …